$28.27+0.30 (+1.07%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Kestra Medical Technologies (KMTS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
14 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~84.9%/yr (FY24→FY26), net margin −138.4%.
The four lines that matter · FY24–FY26
Revenue ($M)▲59.0%
95.1
FY24→FY26CAGR +84.9%/yr
Net income ($M)▼15.6%
−131.6
FY24→FY26CAGR —
Free cash flow ($M)▼16.0%
−116.6
FY24→FY26CAGR —
Diluted EPS▲52.6%
−2.43
FY24→FY26CAGR —
What the income statement says · FY24–FY26
Where every revenue dollar goes · FY26 ($M)
-138¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 1.3% → 51.4%. Net margin -138.4% is below the sector median.
The receipt · income statement · FY24–FY26 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY26 | FY25 | FY24 | YoY | CAGR 24→26 |
|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||
Revenue | 71,415.0 | 95,126.0 | 59,815.0 | 27,814.0 | ▲59.0% | +84.9% |
Cost of revenue | 38,558.0 | 46,263.0 | 35,605.0 | 27,452.0 | ▲29.9% | +29.8% |
Gross profit | 32,857.0 | 48,863.0 | 24,210.0 | 362.0 | ▲101.8% | +1061.8% |
Research & development | 18,447.0 | 19,484.0 | 15,652.0 | 15,490.0 | ▲24.5% | +12.2% |
Selling, general & admin | 129,567.0 | 164,120.0 | 114,936.0 | 69,935.0 | ▲42.8% | +53.2% |
Total operating expenses | 148,014.0 | 183,604.0 | 130,588.0 | 85,425.0 | ▲40.6% | +46.6% |
Operating incomefeeds ROC rank | −115,157.0 | −134,741.0 | −106,378.0 | −85,063.0 | ▼26.7% | — |
Other income, net | −16,766.0 | 3,423.0 | −7,301.0 | −9,033.0 | — | — |
Pretax income | −131,923.0 | −131,318.0 | −113,679.0 | −94,096.0 | ▼15.5% | — |
Income tax | 152.0 | 294.0 | 135.0 | 24.0 | ▲117.8% | +250.0% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −132,075.0 | −131,612.0 | −113,814.0 | −94,120.0 | ▼15.6% | — |
| Per share | ||||||
Diluted EPSbuyback-sensitive | −5.38 | −2.43 | −5.13 | −5.07 | ▲52.6% | — |
Diluted shares (mn) | 58.57 | 54.18 | 24.58 | 19.89 | ▲120.4% | +65.1% |
| Margins | ||||||
Gross margin25th pct in Healthcare | 46.0% | 51.4% | 40.5% | 1.3% | ▲10.9pp | +50.1pp |
Operating margin | −161.3% | −141.6% | −177.8% | −305.8% | ▲36.2pp | +164.2pp |
Net margin8th pct in Healthcare | −184.9% | −138.4% | −190.3% | −338.4% | ▲51.9pp | +200.0pp |
† TTM = trailing four quarters through 2026-07-31.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-07-14 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Kestra Medical Technologies' revenue last fiscal year?
Kestra Medical Technologies reported revenue of $95.1M in fiscal 2026, up 59.0% from fiscal 2025.
What was Kestra Medical Technologies' net income?
Kestra Medical Technologies reported net income of −$131.6M in fiscal 2026, a net margin of −138.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

